EUVIMEDEUVIMED entdecken
Crossref

Enhanced tumor specific drug release by hypoxia sensitive dual-prodrugs based on 2-nitroimidazole

Takashi Tsuji, Honoka Tsunematsu, Masaki Imanishi, Masaya Denda, Koichiro Tsuchiya, Akira Otaka

Bioorganic & Medicinal Chemistry Letters · 2023

DOI: 10.1016/j.bmcl.2023.129484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023. Verfasst von Takashi Tsuji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences, Tokushima University, Tokushima 770-8505, Japan. Hauptthemen laut MEDLINE: Prodrugs, Nitroimidazoles, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia in cancer is important in the development of cancer-selective medicines. Here, a novel hypoxia-responsible dual-prodrug is described. We designed and synthesized 2-nitroimidazole derivatives which spontaneously release both a PYG inhibitor and gemcitabine under hypoxic conditions. One such derivative, a prodrug 9 was found to be stable against chemical and enzymatic hydrolysis, and upon chemical reduction of the nitro group on imidazole, successfully releases both drugs. In an in vitro proliferation assay using human pancreatic cells, compound 9 exhibited significant anti-proliferative effects in hypoxia but fewer effects in normoxia. Consequently, prodrug 9 should be useful for cancer treatment due to its improved cancer selectivity and potential to overcome drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNitroimidazolesAntineoplastic AgentsHumansCell ProliferationCell Line, TumorDrug Screening Assays, AntitumorMolecular StructureDeoxycytidineGemcitabineStructure-Activity RelationshipDrug LiberationCell HypoxiaDose-Response Relationship, Drug

Stichwörter der Autor:innen

GemcitabineHypoxiaNitroimidazoleProdrug

Substanzen

ProdrugsNitroimidazolesAntineoplastic AgentsDeoxycytidineGemcitabine

Autor:innen und Institutionen

  • Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences, Tokushima University, Tokushima 770-8505, Japan.
  • Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences, Tokushima University, Tokushima 770-8505, Japan. Electronic address: aotaka@tokushima-u.ac.jp.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Tsuji, T., Tsunematsu, H., Imanishi, M., Denda, M., Tsuchiya, K., & Otaka, A. (2023). Enhanced tumor specific drug release by hypoxia sensitive dual-prodrugs based on 2-nitroimidazole. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2023.129484

Vancouver

Tsuji T, Tsunematsu H, Imanishi M, Denda M, Tsuchiya K, Otaka A. Enhanced tumor specific drug release by hypoxia sensitive dual-prodrugs based on 2-nitroimidazole. Bioorganic & Medicinal Chemistry Letters. 2023. doi:10.1016/j.bmcl.2023.129484

BibTeX
@article{Tsuji2023,
  author = {Tsuji, Takashi and Tsunematsu, Honoka and Imanishi, Masaki and Denda, Masaya and Tsuchiya, Koichiro and Otaka, Akira},
  title = {Enhanced tumor specific drug release by hypoxia sensitive dual-prodrugs based on 2-nitroimidazole},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2023},
  doi = {10.1016/j.bmcl.2023.129484}
}
Kostenlos starten →